GO
Loading...

Biotechnology

More

  • 2011 Top Stocks: No. 5 Biogen Idec Wednesday, 28 Dec 2011 | 2:59 PM ET

    The No. 5 performer in the top S&P stocks of 2011 could see more growth ahead, one “Fast Money” pro said.

  • Fab Four: Biotech Stocks in 2012     Wednesday, 21 Dec 2011 | 1:44 PM ET

    The biotech sector has surged more than 9% in 2011, so what should investors expect for the new year? Chris Raymond, Robert W. Baird senior biotech analyst, and Karen Anderson, Morningstar senior equity analyst share insight into the sector.

  • Bulls Seek Major Rebound From Targacept Tuesday, 13 Dec 2011 | 6:02 AM ET

    Targacept has been exiled to the woodshed, but yesterday the buyers came back in force.

  • Questcor: A Cheap Biotech Stock Thursday, 17 Nov 2011 | 6:55 PM ET

    Cramer goes one-on-one with Questcor CEO Don Bailey to find out more about the company.

  • Biotech Down Big     Tuesday, 8 Nov 2011 | 2:35 PM ET

    Analysis on why the biotech sector is seeing a down trend, with Raghuram Selvaraju, Morgan Joseph TriArtisan senior vice-president/senior biotechnology analyst.

  • ImmunoGen CEO on New Breast Cancer Drug Monday, 26 Sep 2011 | 6:49 PM ET

    Daniel Junius talks to Cramer about the drug’s recent trial, which was good news for the company’s stock, and when the FDA could get it for approval.

  • ImmunoGen Gets Positive Data on New Drug     Monday, 26 Sep 2011 | 6:48 PM ET

    In this volatile market, investors need stocks that will keep them interested even when things are at their most bleak, says Mad Money host, Jim Cramer. Discussing the next-generation of cancer treatments with biotech developer, Daniel Julies, ImmunoGen CEO.

  • Cramer makes the call on viewers' favorite stocks.

  • Herb on the Street: Dendreon     Thursday, 4 Aug 2011 | 9:37 AM ET

    CNBC's Herb Greenberg reports the biotech company missed sales guidance in a big way.

  • Biogen: An Impressive Turnaround?     Tuesday, 26 Jul 2011 | 3:40 PM ET

    Discussing whether the company's restructuring efforts has paid off, and its ability to compete in the big pharma space, with George Scangos, Biogen CEO.

  • Cramer makes the call on viewers' favorite stocks.

  • Actelion Will Stay Independent: Founder Thursday, 21 Jul 2011 | 1:49 AM ET

    The chief executive and founder of Actelion, one of the world's biggest biotechnology companies, said the firm would stay independent despite pressure from activist shareholders.

  • Cramer Interviews Celgene CEO Hugin Thursday, 30 Jun 2011 | 7:00 PM ET

    The biotech company's top executive discusses its product line, future prospects and the biotech industry in general.

  • FDA Hearing on Avastin     Tuesday, 28 Jun 2011 | 6:47 AM ET

    The FDA begins hearings on the effectiveness of Genentech's breast cancer drug reports CNBC's Hampton Pearson.

  • Biotech's Healthy Growth     Monday, 27 Jun 2011 | 6:31 AM ET

    Biotech is projected to expand at an annual rate of 1.5%. A look at innovation and growth in the industry, with Jim Greenwood, Biotechnology Industry Organization president/CEO.

  • Pacific Biosciences—A Spec Stock Worth the Risk? Friday, 24 Jun 2011 | 6:16 PM ET

    Cramer thinks so. Here's why.

  • Lightning Round OT: Seattle Genetics, IBM and More Wednesday, 22 Jun 2011 | 8:02 PM ET

    The Lightning Round is extended in this CNBC.com exclusive feature.

  • Expanding Biotech in Boston     Wednesday, 22 Jun 2011 | 10:40 AM ET

    Weighing in on why Boston is the right place for biotech or not, with Matthew Emmens, Vertex CEO and Gov. Deval Patrick (D-MA).

  • Biotech Analyst Bullish on BIIB     Monday, 20 Jun 2011 | 5:41 PM ET

    Mark Schoenebaum, ISI Group analyst, explains how BIIB can triple its dividend in three years. "This growth exists nowhere else in large cap pharma or biotech," he says.

  • Biotech VC Enjoys Record Profits     Tuesday, 14 Jun 2011 | 5:50 PM ET

    Alexis Borisy, Third Rock Ventures, discusses record-breaking aggregate net profit for biotech centers in the United States. "Personalized medicine is on the verge of being monetized," he tells Fast Money.